Beiträge in Fachzeitschriften

 

2018

Langhof, H., Kahrass, H., Illig, T., Jahns, R., & Strech, D. Current practices for access, compensation, and prioritization in biobanks. Results from an interview study. European Journal of Human Genetics. doi:10.1038/s41431-018-0228-x.

Dahl E. Biobanking und die Weiterentwicklung der Präzisionsmedizin. Der Pathologe, DOI: 10.1007/s00292-018-0449-3.

Dahl E, Schirmmacher P, Knüchel R. Biobanken - Eine zentrale Aufgabe der Pathologie. Der Pathologe, DOI 10.1007/s00292-018-0448-4

Schüttler C, Buschhüter N, Döllinger C, Ebert L, Hummel M, Linde J, Prokosch H.-U, Proynova R, Lablans M. Anforderungen an eine standortübergreifende Biobanken-IT-Infrastruktur. Der Pathologe, April 2018, 10.1007/s00292-018-0435-9.

Becker K.-F, Wipperfürth J, Herpel E. Präanalytik und Biobanking. Der Pathologe, April 2018, 10.1007/s00292-018-0437-7.

Koschmieder S, Brümmendorf T. H. Biobankinganforderungen aus Sicht des Klinikers. Erfahrungen aus der Hämatologie und Onkologie. Der Pathologe, April 2018, 10.1007/s00292-018-0434-x.

2017

Kloten V, Rüchel N, Ortiz-Brüchle N, Gasthaus J, Freudenmacher N, Steib F, Mijnes J, Eschenbruch J, Binnebösel M, Knüchel R, Dahl E.
Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR.Oncotarget. 2017 Sep 21;8(49):86253-86263. doi: 10.18632.

Woitok M, Klose D, Di Fiore S, Richter W, Stein C, Gresch G, et al.
Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells. Onco Targets Ther. 2017 Jul 6;10:3313-3327.

Garczyk S, Klotz N, Szczepanski S, Denecke B, Antonopoulos W, von Stillfried S, Knüchel R, Rose M, Dahl E.
Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway. Oncotarget. 2017 May 30;8(22):36246-36265. doi: 10.18632/oncotarget.16121.

2016

Dahl E.
Diagnostik: Liquid Biopsy – Status 2016. Dtsch Arztebl 2016; 113(39): [4]; DOI: 10.3238/PersOnko/2016.09.30.01.

Schlensog M, Magnus L, Heide T, Eschenbruch J, Steib F, Tator M, Kloten V, Rose M, Noetzel E, Gaisa NT, Knüchel R, Dahl E.
Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients. Epigenetics; DOI: 10.1080/15592294.2016.1229730.

Dahl E.
Aufbau einer zentralisierten Biobank. Komplexer als erwartet. Trillium - Medizinischer Fachverlag; In-vitro-Diagnostik.

2015

Bauerschlag D, Maass N, Leonhardt P, Verburg F. A, Pecks U, Zeppernick F, Morgenroth A, Mottaghy F. M, Tolba R, Meinhold-Heerlein I, Bräutigam K.
Fatty Acid Synthase Overexpression: Target for Therapy and Reversal of Hemoresistance in Ovarian Cancer. Journal of Translational Medicine 2015 13, 146 - 158.

Dahl E, Jung A, Fassunke J, Hummel M, Penzel R, Dietmaier W, Laßmann S.
Chancen und Risiken der blutbasierten molekularpathologischen Analytik zirkulierender Tumorzellen (CTC) und zellfreier DNA (cfDNA) in der personalisierten Krebstherapie. Pathologe 2015 36, 92–97.

Huth S, Heise R, Vetter-Kauczok C. S, Skazik C, Marquardt Y, Czaja K, Knüchel-Clarke R, Merk H. F, Dahl E, Baron J. M.
Inter-a-trypsin inhibitor heavy chain 5 (ITIH5) is overexpressed in inflammatory skin diseases and affects epidermal morphology in constitutive knockout mice and murine 3D skin models. Experimental Dermatology, 2015 24, 663–668.

Leusmann P, Veeck J, Jäkel J, Dahl E, Knüchel-Clarke R, Spreckelsen C.
Towards Sustainable Data Management in Professional Biobanking. Studies in Health Technology and Informatics. Volume 212: eHealth2015 - Health Informatics Meets eHealth, 94 - 102.

Martin L, Schmitz S, De Santis R, Doemming S, Haase H, Hoeger J, Heinbockel L, Brandenburg K, Marx G, Schuerholz T.
Peptide 19-2.5 Inhibits Heparan Sulfate-Triggered Inflammation in Murine Cardiomyocytes Stimulated with Human Sepsis Serum. PLOS ONE 10(5): e0127584.

2014

Antony P, Rose M, Heidenreich A, Knüchel-Clarke R, Gaisa N. T, Dahl E.
Epigenetic Inactivation of ST6GAL1 in Human Bladder Cancer. BMC Cancer 2014 14, 901.

Huth L, Rose M, Kloubert V, Winkens W, Schlensog M, Hartmann A, Knüchel-Clarke R, Dahl E.
BDNF Is Associated with SFRP1 Expression in Luminal and Basal-Like Breast Cancer Cell Lines and Primary Breast Cancer Tissues: A Novel Role in Tumor Suppression? PLOS ONE July 2014 | Volume 9 | Issue 7 | e102558

Kloten V, Rose M, Kaspar S, von Stillfried S, Knüchel-Clarke R, Dahl E.
Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype. Epigenetics 2014 9(9), 1290 - 1301.

Rose M, Schubert C, Dierichs L, Gaisa N. T, Heer M, Heidenreich A, Knüchel-Clarke R, Dahl E.
OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro. Epigenetics 2014 9(12), 1626 - 1640.

Kahles F, Meyer C, Möllmann J, Diebold S, Findeisen H. M, Lebherz C, Trautwein C, Koch A, Tacke F, Marx N, Lehrke M.
GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6–Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering. Diabetes 2014 63, 3221–3229.

2013

Dahl E, Haller F.
Personalized urooncology based on molecular uropathology: what is the future? Urologe A. 2013 Jul;52(7):976-81. doi: 10.1007/s00120-013-3229-y. German.

Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knüchel R, Dahl E.
Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 2013 Jan 15;15(1):R4. doi: 10.1186/bcr3375.